TY - JOUR
T1 - Viral retinitis following intraocular or periocular corticosteroid administration
T2 - A case series and comprehensive review of the literature
AU - Takakura, Ako
AU - Tessler, Howard H.
AU - Goldstein, Debra A.
AU - Guex-Crosier, Yan
AU - Chan, Chi Chao
AU - Brown, Diane M.
AU - Thorne, Jennifer E.
AU - Wang, Robert
AU - Cunningham, Emmett T.
N1 - Funding Information:
Supported in part by the Pacific Vision Foundation and the Retina Foundation.
PY - 2014/6
Y1 - 2014/6
N2 - Purpose: To describe viral retinitis following intravitreal and periocular corticosteroid administration. Methods: Retrospective case series and comprehensive literature review. Results: We analyzed 5 unreported and 25 previously published cases of viral retinitis following local corticosteroid administration. Causes of retinitis included 23 CMV (76.7%), 5 HSV (16.7%), and 1 each VZV and unspecified (3.3%). Two of 22 tested patients (9.1%) were HIV positive. Twenty-one of 30 (70.0%) cases followed one or more intravitreal injections of triamcinolone acetonide (TA), 4 (13.3%) after one or more posterior sub-Tenon injections of TA, 3 (10.0%) after placement of a 0.59-mg fluocinolone acetonide implant (Retisert), and 1 (3.3%) each after an anterior subconjunctival injection of TA (together with IVTA), an anterior chamber injection, and an anterior sub-Tenon injection. Mean time from most recent corticosteroid administration to development of retinitis was 4.2 months (median 3.8; range 0.25-13.0). Twelve patients (40.0%) had type II diabetes mellitus. Treatments used included systemic antiviral agents (26/30, 86.7%), intravitreal antiviral injections (20/30, 66.7%), and ganciclovir intravitreal implants (4/30, 13.3%). Conclusions: Viral retinitis may develop or reactivate following intraocular or periocular corticosteroid administration. Average time to development of retinitis was 4 months, and CMV was the most frequently observed agent. Diabetes was a frequent co-morbidity and several patients with uveitis who developed retinitis were also receiving systemic immunosuppressive therapy.
AB - Purpose: To describe viral retinitis following intravitreal and periocular corticosteroid administration. Methods: Retrospective case series and comprehensive literature review. Results: We analyzed 5 unreported and 25 previously published cases of viral retinitis following local corticosteroid administration. Causes of retinitis included 23 CMV (76.7%), 5 HSV (16.7%), and 1 each VZV and unspecified (3.3%). Two of 22 tested patients (9.1%) were HIV positive. Twenty-one of 30 (70.0%) cases followed one or more intravitreal injections of triamcinolone acetonide (TA), 4 (13.3%) after one or more posterior sub-Tenon injections of TA, 3 (10.0%) after placement of a 0.59-mg fluocinolone acetonide implant (Retisert), and 1 (3.3%) each after an anterior subconjunctival injection of TA (together with IVTA), an anterior chamber injection, and an anterior sub-Tenon injection. Mean time from most recent corticosteroid administration to development of retinitis was 4.2 months (median 3.8; range 0.25-13.0). Twelve patients (40.0%) had type II diabetes mellitus. Treatments used included systemic antiviral agents (26/30, 86.7%), intravitreal antiviral injections (20/30, 66.7%), and ganciclovir intravitreal implants (4/30, 13.3%). Conclusions: Viral retinitis may develop or reactivate following intraocular or periocular corticosteroid administration. Average time to development of retinitis was 4 months, and CMV was the most frequently observed agent. Diabetes was a frequent co-morbidity and several patients with uveitis who developed retinitis were also receiving systemic immunosuppressive therapy.
KW - Acute retinal necrosis
KW - Corticosteroid
KW - Cytomegalovirus
KW - Herpes virus
KW - Injection
KW - Retinitis
UR - http://www.scopus.com/inward/record.url?scp=84901398380&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901398380&partnerID=8YFLogxK
U2 - 10.3109/09273948.2013.866256
DO - 10.3109/09273948.2013.866256
M3 - Article
C2 - 24655372
AN - SCOPUS:84901398380
SN - 0927-3948
VL - 22
SP - 175
EP - 182
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
IS - 3
ER -